The role of UDCA in gallstones resolution has been widely debated and it is still a longstanding primary treatment of this syndrome. We explored on 20 patients both sex, randomly assigned, the feasibility, advantages, and drawbacks of intravenous high UDCA dosages intravenous perfusion compared with the same amount of bile salt oral delivery. The primary clinical endpoint was stones disappearance and the surrogate endpoint was the relieve of colicky pain symptoms and liver enzymes improvement. Notwithstanding the bias due to small cases number, the evidence is definitely in favor of parenteral treatment which is very effective especially in the acute control of pain, vomitus and nausea, when oral drugs and feeding is not advisable.